Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 74% · stale
- Computed at
- 2026-09-22T23:27:14.984527+00:00
- Claimed
- 45
- Reported
- 38
- Verified
- 33
- Gap
- +12
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-09-22
Proceed with caution
- Why
- Reassuring safety signal and intriguing female lean-mass/pain effects, but the primary endpoint failed and the dosing/cohort weaknesses make efficacy claims premature.
- Next
- Wait for an adequately powered, sex-balanced trial using commercial-bioavailability rapamycin and a pre-registered primary endpoint before treating any healthspan claim as established; do not infer mortality/disease benefit, which remains unproven in healthy adults.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 5
- Tier 2
- 3
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 4
- Context
- 2
- Latest observed
- 2025-12-11
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 2
- 2026-07-19 Reading moved from emerging to emerging.
- 2026-09-22 Reading moved from emerging to emerging.